Innovative biotherapies and genetic eye diseases


 

AFM/L.Audinet

Innovative biotherapies and genetic eye diseases: the Réseau Thérapie Génique Oculaire (Ocular Gene Therapy Network) prepares to launch human trials

Tomorrow, around thirty innovative biotherapy and genetic eye disease experts* will gather together at Généthon (Evry) to review, for the first time, the studies carried out so far as part of the Réseau Thérapie Génique Oculaire (R-TGO – Ocular Gene Therapy Network).

The network was launched in 2009 by Généthon and is co-led by José-Alain Sahel (Institut de la Vision, Paris), Fabienne Rolling (Nantes) and Laurence Tiennot-Herment (Généthon/Association Française contre les Myopathies). Made up of project teams, representatives from centres of excellence in the field of eye diseases and gene therapy experts from the Généthon laboratory, its objective is to accelerate the launch of gene therapy trials for genetic eye diseases in the next five years.